Peptides: Prospects for Use in the Treatment of COVID-19
| Autor: | Khavinson Vladimir Kh, Natalia Linkova, Roman Umnov, Kuznik Bi, Anastasiia Dyatlova |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Anti-Inflammatory Agents Respiratory System Agents Pharmaceutical Science Review 030204 cardiovascular system & hematology Pharmacology drugs Analytical Chemistry 0302 clinical medicine Drug Discovery Lung Disseminated intravascular coagulation immunomodulators Cytokine release syndrome medicine.anatomical_structure Chemistry (miscellaneous) Acute Disease Host-Pathogen Interactions Molecular Medicine medicine.symptom Coronavirus Infections Cytokine Release Syndrome Respiratory Insufficiency Pneumonia Viral Antiviral Agents Virus lcsh:QD241-441 03 medical and health sciences Betacoronavirus Structure-Activity Relationship lcsh:Organic chemistry Immunity medicine Humans Immunologic Factors Physical and Theoretical Chemistry Pathological Pandemics business.industry SARS-CoV-2 Organic Chemistry COVID-19 Disseminated Intravascular Coagulation medicine.disease immunity 030104 developmental biology Mechanism of action Hemostasis hemostasis peptides business |
| Zdroj: | Molecules Molecules, Vol 25, Iss 4389, p 4389 (2020) |
| ISSN: | 1420-3049 |
| Popis: | There is a vast practice of using antimalarial drugs, RAS inhibitors, serine protease inhibitors, inhibitors of the RNA-dependent RNA polymerase of the virus and immunosuppressants for the treatment of the severe form of COVID-19, which often occurs in patients with chronic diseases and older persons. Currently, the clinical efficacy of these drugs for COVID-19 has not been proven yet. Side effects of antimalarial drugs can worsen the condition of patients and increase the likelihood of death. Peptides, given their physiological mechanism of action, have virtually no side effects. Many of them are geroprotectors and can be used in patients with chronic diseases. Peptides may be able to prevent the development of the pathological process during COVID-19 by inhibiting SARS-CoV-2 virus proteins, thereby having immuno- and bronchoprotective effects on lung cells, and normalizing the state of the hemostasis system. Immunomodulators (RKDVY, EW, KE, AEDG), possessing a physiological mechanism of action at low concentrations, appear to be the most promising group among the peptides. They normalize the cytokines’ synthesis and have an anti-inflammatory effect, thereby preventing the development of disseminated intravascular coagulation, acute respiratory distress syndrome and multiple organ failure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|